Core Insights - The Shanghai biopharmaceutical industry is experiencing significant growth, projected to reach a scale of 1 trillion yuan by 2024, with a compound annual growth rate of 8.94% from 2021 to 2024 [2] - The industry is recognized as a strategic emerging sector, receiving national attention and support, with plans to allocate more resources and policy backing during the 14th Five-Year Plan [2][10] - Shanghai is establishing itself as a global hub for biopharmaceutical innovation, with a focus on high-end, intelligent, and international development [8][10] Industry Growth and Scale - The biopharmaceutical industry in Shanghai grew from 761.71 billion yuan in 2021 to an expected 984.70 billion yuan in 2024, with the first half of 2025 projected at 500.57 billion yuan [2] - China's biopharmaceutical market reached 2.95 trillion yuan in 2023, leading globally in chemical raw material drug exports, drug formulation capacity, and vaccine supply [2] Regional Cluster Advantages - Shanghai, Guangdong, and Beijing exhibit significant advantages in biopharmaceutical industry clusters, with Shanghai hosting 19 of the top 20 global pharmaceutical giants [3] - The local ecosystem includes innovative companies such as Fosun Pharma and Junshi Biosciences, fostering resource sharing and collaborative innovation [3] Innovation and Research - During the 13th Five-Year Plan, Shanghai achieved breakthroughs in synthetic biology, stem cell research, and neuroscience, supported by 17 national key laboratories [7] - The number of patent applications in the biopharmaceutical sector in Shanghai has been rapidly increasing, surpassing 8,000 in 2020 [7] Policy and Investment Support - The Shanghai government has established a 22.5 billion yuan biopharmaceutical industry mother fund, with a leverage ratio of 5.59 times [10] - The city aims to enhance its policy framework for the entire biopharmaceutical innovation chain and promote global collaboration [10] Future Outlook - The biopharmaceutical industry is set to become a new economic pillar for Shanghai, alongside artificial intelligence and integrated circuits, creating a core framework for future industrial development [10]

构建人工智能创新生态，助力上海构建人工智能创新策源地。 本文为IPO早知道原创 作者｜苏打 微信公众号｜ipozaozhidao 据IPO早知道消息，2024年12月30日，上海三大先导产业母基金首批遴选生态合作伙伴签约暨第二 批遴选申报发布仪式在上海举行。 现场， 上海国投公司与浦东新区共同发布上海具身智能基金、与徐汇区共同发布上海大模型基金， 旨在发掘人工智能领域相关科技创新项目，构建人工智能创新生态，助力上海构建人工智能创新策源 地 。 仪式上，三大先导产业母基金管理公司与首批12家生态合作基金正式签约，共认缴出资67亿，基金 总规模250亿，放大倍数3.73倍。市相关部门共同发布上海三大先导产业母基金第二批遴选申报， 彰显了上海市各相关部门在促进三大先导产业发展和创新升级方面的紧密协同和鼎力支持。 部分"上海国投"系基金管理人围绕三大先导产业生态圈建设，分别与相关生态合作伙伴签约，进一 步巩固产业链上下游的协同关系。生态合作基金代表包括启明创投、中科创星、礼来亚洲等。 为贯彻落实11月27日上海市与部分中央金融机构负责人座谈会精神，上海国投公司与新华保险、国 开行上海分行、国寿资产、中信证券等金融机构 ...